Kane Biotech Inc. KNBIF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -97.88% | -97.59% | -80.38% | -72.63% | 141.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -97.88% | -97.59% | -80.38% | -72.63% | 141.30% |
| Cost of Revenue | -97.14% | -93.22% | -65.94% | -36.66% | 354.50% |
| Gross Profit | -100.03% | -105.31% | -100.25% | -109.52% | 2.44% |
| SG&A Expenses | -14.21% | -53.35% | -37.60% | -52.49% | -30.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.78% | -64.26% | -49.23% | -47.27% | -13.10% |
| Operating Income | 6.63% | 41.94% | 31.78% | 35.02% | 38.80% |
| Income Before Tax | 14.50% | 44.15% | 38.44% | 35.92% | 41.33% |
| Income Tax Expenses | 92.35% | 92.05% | 91.72% | -- | -- |
| Earnings from Continuing Operations | -36.25% | 22.51% | 17.05% | 61.82% | 64.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -112.16% | -111.70% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.61% | -134.49% | -143.26% | -156.72% | -166.27% |
| EBIT | 6.63% | 41.94% | 31.78% | 35.02% | 38.80% |
| EBITDA | 6.05% | 44.06% | 33.91% | 37.71% | 40.05% |
| EPS Basic | 28.80% | -124.02% | -137.35% | -155.81% | -173.46% |
| Normalized Basic EPS | 23.68% | 63.45% | 48.70% | 41.18% | 41.24% |
| EPS Diluted | 20.00% | -143.48% | -163.80% | -180.23% | -221.88% |
| Normalized Diluted EPS | 23.68% | 61.59% | 46.26% | 38.65% | 39.04% |
| Average Basic Shares Outstanding | 49.16% | 70.98% | 55.94% | 33.86% | 0.77% |
| Average Diluted Shares Outstanding | 49.16% | 62.67% | 48.50% | 27.79% | -3.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |